The benefit of Canagliflozin is more apparent than real in non-T2DM patient, as 6.7% reduction would not usually get you to target ( think change from 6.4 to 6 mg). The prophylactic value might be more important in T2DM patient, if co-existed, as one might not require another agent like Colchicine or NSAID (with the latter might be undesirable not infrequently in diabetic). As for non-diabetic, there is hardly any reason to use SLGT2 for either purpose with the other established choices. Nevertheless, nice to know the findings.